Skip to content
TriangleGet started
← Full study record

NCT05198934 · OUTCOME

Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by BICR

Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation · Source last updated 2026-07-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
From randomization until DCO or death; median (min, max) time on trial was 6.23 (0.1, 14.0) months

What was measured

PFS was defined as time from randomization until disease progression or death from any cause, whichever occurred first, for all participants. Progression was assessed using RECIST v1.1 per BICR.

Analysis population: FAS included all randomized participants.

Groups in this outcome

Trifluridine and Tipiracil or Regorafenib

Participants received investigator's choice of trifluridine and tipiracil or regorafenib. Treatment continued until progressive disease, intolerance to treatment necessitating treatment discontinuation, need for other anticancer therapy, withdrawal of consent, or death.

Sotorasib 240 mg + Panitumumab

Participants received sotorasib 240 mg QD in combination with panitumumab. Treatment continued until progressive disease, intolerance to treatment necessitating treatment discontinuation, need for other anticancer therapy, withdrawal of consent, or death.

Sotorasib 960 mg + Panitumumab

Participants received sotorasib 960 mg QD in combination with panitumumab. Treatment continued until progressive disease, intolerance to treatment necessitating treatment discontinuation, need for other anticancer therapy, withdrawal of consent, or death.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Trifluridine and Tipiracil or Regorafenib54
Sotorasib 240 mg + Panitumumab53
Sotorasib 960 mg + Panitumumab53

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Trifluridine and Tipiracil or Regorafenib2.04Not reported1.913.91Not reported
Sotorasib 240 mg + Panitumumab3.91Not reported3.615.75Not reported
Sotorasib 960 mg + Panitumumab5.62Not reported4.216.31Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1.91
        upper Limit
        3.91
        value
        2.04
      2. group Id
        OG001
        lower Limit
        3.61
        upper Limit
        5.75
        value
        3.91
      3. group Id
        OG002
        lower Limit
        4.21
        upper Limit
        6.31
        value
        5.62
denoms
  1. counts
    1. group Id
      OG000
      value
      54
    2. group Id
      OG001
      value
      53
    3. group Id
      OG002
      value
      53
    units
    Participants
description
PFS was defined as time from randomization until disease progression or death from any cause, whichever occurred first, for all participants. Progression was assessed using RECIST v1.1 per BICR.
dispersion Type
95% Confidence Interval
groups
  1. description
    Participants received investigator's choice of trifluridine and tipiracil or regorafenib. Treatment continued until progressive disease, intolerance to treatment necessitating treatment discontinuation, need for other anticancer therapy, withdrawal of consent, or death.
    id
    OG000
    title
    Trifluridine and Tipiracil or Regorafenib
  2. description
    Participants received sotorasib 240 mg QD in combination with panitumumab. Treatment continued until progressive disease, intolerance to treatment necessitating treatment discontinuation, need for other anticancer therapy, withdrawal of consent, or death.
    id
    OG001
    title
    Sotorasib 240 mg + Panitumumab
  3. description
    Participants received sotorasib 960 mg QD in combination with panitumumab. Treatment continued until progressive disease, intolerance to treatment necessitating treatment discontinuation, need for other anticancer therapy, withdrawal of consent, or death.
    id
    OG002
    title
    Sotorasib 960 mg + Panitumumab
param Type
MEDIAN
population Description
FAS included all randomized participants.
reporting Status
POSTED
time Frame
From randomization until DCO or death; median (min, max) time on trial was 6.23 (0.1, 14.0) months
title
Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by BICR
type
PRIMARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Independent clinical review pending · Not medical advice